VBL to present positive VB-111 preclinical data in metastatic lung cancer at 14th ASGCT

May 20 2011

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced that it will present preclinical data demonstrating VB-111's potential synergy and additive therapeutic effect when administered in combination with the conventional chemotherapy cancer treatments. The company will present data demonstrating this synergistic effect in an in vivo preclinical model of metastatic lung cancer at 4:40 p.m. PT today at the 14^th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) at the Washington State Convention Center in Seattle.

“We are pleased to present these compelling data at ASGCT”

VB-111 is the first targeted, dual-action, anti-angiogenic and Vascular Disruptive Agent (VDA) to use VTS^™, the company's proprietary platform technology, for cancer therapy. VB-111 is an IV-administered VDA that works in a manner akin to a "biological knife" to destroy tumor vasculature, thus cutting off the blood vessels feeding the tumor. VB-111 is currently being investigated in Phase 2 clinical studies in thyroid cancer and in glioblastoma.

"We are pleased to present these compelling data at ASGCT," said Eyal Breitbart, Ph.D., vice president of research at VBL. "These studies continue to demonstrate VB-111's promise as a targeted cancer treatment and illustrate its potential to work synergistically in combination with conventional chemotherapy treatments to provide a more effective treatment regimen for cancer patients. Importantly, VB-111's unique mechanism of action targets tumors with precision and specificity, causing no significant damage to the normal non-cancerous tissue or vasculatures in the body."

The studies demonstrated that VB-111 as a combined therapy with the chemotherapy doxorubicin in a Lewis Lung metastasis model showed additive effect compared to treatment with VB-111 alone. Additionally, additive effect was also seen after treatment with a lower dose of VB-111 in combination with paclitaxel compared to treatment with either VB-111 or paclitaxel alone. No toxicity was observed as a result of these combined therapies, and the treated groups were found to have normal growth pathology with no lesions or evidence of metastasis.